Protalix BioTherapeutics, Inc. Financing Cash Flow
Protalix BioTherapeutics, Inc. (PLX) reported Financing Cash Flow of $150.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- Protalix BioTherapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Protalix BioTherapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $150.00K, a 97.04% decline year-over-year.
- Protalix BioTherapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $146.00K, a 95.97% decline year-over-year.
- Protalix BioTherapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00.
- Protalix BioTherapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $9.33M.
- Protalix BioTherapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was -$16.79M, a 168.09% decline from fiscal 2023.
- Protalix BioTherapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $24.67M, a 199.42% increase from fiscal 2022.
- Protalix BioTherapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $8.24M, a 31.79% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $150.00K 10-Q · filed 2026-08-12 | $296.00K derived: sum of 3 quarters · filed 2026-08-12 | $296.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $150.00K 10-Q · filed 2026-05-13 | $296.00K derived: sum of 2 quarters · filed 2026-05-13 | $296.00K derived: sum of 3 quarters · filed 2026-05-13 | $4.40M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $146.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $146.00K derived: sum of 2 quarters · filed 2026-03-18 | $4.25M derived: sum of 3 quarters · filed 2026-08-12 | $9.33M 10-K · filed 2026-03-18 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $4.10M derived: sum of 2 quarters · filed 2026-08-12 | $9.18M 10-Q · filed 2025-11-13 | $12.81M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $4.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $9.18M 10-Q · filed 2026-08-12 | $12.81M derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-03-31 | $5.08M 10-Q · filed 2026-05-13 | $8.70M derived: sum of 2 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $3.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$16.79M 10-K · filed 2026-03-18 | ||
| 2024-09-30 | -$20.42M 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $0.00 derived: sum of 2 quarters · filed 2026-03-18 | $10.43M derived: sum of 3 quarters · filed 2026-03-18 | $24.67M 10-K · filed 2026-03-18 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $10.43M derived: sum of 2 quarters · filed 2024-11-14 | $24.67M 10-Q · filed 2024-11-14 | $28.74M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $10.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $24.67M 10-Q · filed 2024-08-14 | $28.74M derived: sum of 3 quarters · filed 2025-03-17 | $30.26M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $14.23M 10-Q · filed 2024-05-10 | $18.31M derived: sum of 2 quarters · filed 2025-03-17 | $19.83M derived: sum of 3 quarters · filed 2025-03-17 | |
| 2022-12-31 | $4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $5.59M derived: sum of 2 quarters · filed 2025-03-17 | $8.24M 10-K · filed 2025-03-17 | |
| 2022-09-30 | $1.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $4.16M 10-Q · filed 2023-11-06 | ||
| 2022-06-30 | $2.64M 10-Q · filed 2023-08-07 | |||
| 2021-12-31 | -$4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$30.04M derived: sum of 2 quarters · filed 2024-03-14 | -$30.04M derived: sum of 3 quarters · filed 2024-03-14 | $12.08M 10-K · filed 2024-03-14 |
| 2021-09-30 | -$25.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$25.99M derived: sum of 2 quarters · filed 2022-11-14 | $16.12M 10-Q · filed 2022-11-14 | $20.78M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $42.11M 10-Q · filed 2022-08-15 | $46.77M derived: sum of 3 quarters · filed 2023-02-27 | $51.24M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $42.11M 10-Q · filed 2022-05-16 | $46.77M derived: sum of 2 quarters · filed 2023-02-27 | $51.24M derived: sum of 3 quarters · filed 2023-02-27 | $49.97M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $4.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $9.12M derived: sum of 2 quarters · filed 2023-02-27 | $7.86M derived: sum of 3 quarters · filed 2023-02-27 | $46.47M 10-K · filed 2023-02-27 |
| 2020-09-30 | $4.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $3.21M derived: sum of 2 quarters · filed 2021-11-15 | $41.81M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $37.34M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $38.61M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $0.00 10-K · filed 2020-03-12 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $0.00 derived: sum of 2 quarters · filed 2021-03-30 | -$4.75M 10-K · filed 2021-03-30 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$4.75M 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | -$4.75M 10-Q · filed 2019-08-08 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $9.54M derived: sum of 2 quarters · filed 2020-03-12 | $5.31M derived: sum of 3 quarters · filed 2020-03-12 | -$1.42M 10-K · filed 2020-03-12 |
| 2017-09-30 | $9.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-03-18 | $5.31M derived: sum of 2 quarters · filed 2019-03-18 | -$1.42M 10-Q · filed 2019-03-18 | $18.28M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-06-30 | -$4.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-03-18 | -$10.96M 10-Q · filed 2019-03-18 | $8.73M derived: sum of 3 quarters · filed 2019-03-18 | |
| 2017-03-31 | -$6.73M 10-Q · filed 2019-03-18 | $12.97M derived: sum of 2 quarters · filed 2019-03-18 | ||
| 2016-12-31 | $19.70M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $19.70M 10-K · filed 2019-03-18 | ||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-08 | |||
| 2015-12-31 | $6.63M 10-K · filed 2018-03-06 | |||
| 2013-09-30 | $66.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $66.96M 10-Q · filed 2013-11-07 | ||
| 2013-06-30 | $30.00K 10-Q · filed 2013-08-08 | |||
| 2012-12-31 | $134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | -$6.00K derived: sum of 2 quarters · filed 2013-11-07 | $984.00K derived: sum of 3 quarters · filed 2013-11-07 | $26.56M 10-K · filed 2013-02-28 |
| 2012-09-30 | -$140.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $850.00K derived: sum of 2 quarters · filed 2013-11-07 | $26.42M 10-Q · filed 2013-11-07 | $26.44M derived: sum of 4 quarters · filed 2013-11-07 |
| 2012-06-30 | $990.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $26.56M 10-Q · filed 2013-08-08 | $26.58M derived: sum of 3 quarters · filed 2013-08-08 | $26.58M derived: sum of 4 quarters · filed 2013-08-08 |
| 2012-03-31 | $25.57M 10-Q · filed 2013-05-09 | $25.59M derived: sum of 2 quarters · filed 2013-05-09 | $25.59M derived: sum of 3 quarters · filed 2013-05-09 | $25.57M derived: sum of 4 quarters · filed 2013-05-09 |
| 2011-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $18.00K derived: sum of 2 quarters · filed 2013-02-28 | -$9.00K derived: sum of 3 quarters · filed 2013-02-28 | $20.93M 10-K · filed 2013-02-28 |
| 2011-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | -$23.00K derived: sum of 2 quarters · filed 2012-11-07 | $20.91M 10-Q · filed 2012-11-07 | $21.25M derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-06-30 | -$27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $20.91M 10-Q · filed 2012-08-03 | $21.25M derived: sum of 3 quarters · filed 2013-02-28 | $21.38M derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-03-31 | $20.94M 10-Q · filed 2012-05-09 | $21.28M derived: sum of 2 quarters · filed 2013-02-28 | $21.41M derived: sum of 3 quarters · filed 2013-02-28 | |
| 2010-12-31 | $342.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $474.00K derived: sum of 2 quarters · filed 2013-02-28 | $501.00K 10-K · filed 2013-02-28 | |
| 2010-09-30 | $132.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | $159.00K 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | $27.00K 10-Q · filed 2011-08-08 | |||
| 2009-12-31 | $293.00K 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |